Migraine Trials

Allergan 304

This is a double-blind study that evaluates the efficacy, safety, and tolerability of oral Ubrogepant in acute treatment of migraines during the prodrome (preheadache). The goal is to treat the warning symptoms (photophobia, nausea, neck pain, etc.) to prevent migraines from occurring. Ubrogepant is an oral CGRP-RA (Calcitonin Gene-Related Peptide Receptor Antagonist) under investigation for migraine treatment. CGRP is a neuropeptide, found during migraine pain. It is thought that interrupting CGRP will interrupt migraine pain and give people relief. The study is 4 months long and has 4 visits.

Allergan 312

Allergan 312 is an open-label extension study that evaluates the long-term safety, and tolerability of oral atogepant for the prevention of migraines in participants with chronic migraines (15 or more migraines per month). Atogepant is an oral CGRP (which stands for Calcitonin Gene-Related Peptide) receptor antagonist under investigation for migraine treatment. The study is 52 weeks long, and has 10 visits. In order to be eligible, participants must complete the Allergan 303 (chronic migraine) clinical trial.

M21-307, Sponsored by Abbvie

The M21-307 Trial is researching an investigational medication to treat episodic migraines. Migraines are headaches of moderate or severe intensity and may also include symptoms of nausea, vomiting, and sensitivity to light and sounds. A patient with episodic migraine experiences headaches on less than 15 days per month. The study drug has been approved by the regulatory authorities for use in people with chronic migraine and other specific medical conditions but is not yet approved for the prevention of episodic migraines which is why the study is being carried out.
We are looking for:
·       Are between 18 and 65 years of age
·       Have a diagnoses of migraine
·       Experience 6 to 14 migraine days a month
The study will last approximately one year. In person study visits will take place about every three months at the study site. You will also receive monthly telephone calls from the site to monitor your status.

News

Dr. Weisman and His Patients Featured in Article About MCI

March 6, 2024 No Comments

In neurology we learn the same lessons again and again: Time is brain.

ANA Featured in Washington Post Article About Leqembi

January 29, 2024 No Comments

Lecanemab has not been as widely tested in Black patients.

Dr. Weisman Quoted in Article about Quest Rapid Alzheimer’s Test

September 12, 2023 No Comments

Almost anyone can take this quick test for Alzheimer’s without even going to the doctor….

An Open Letter to Highmark and Independence Blue Cross

September 8, 2023 No Comments

Denial of coverage for lecanemab will have devastating consequences for millions of patients and families.

FDA Converts Lecanemab to Traditional Approval

July 6, 2023 No Comments

Leqembi is the first amyloid beta-directed antibody to be converted from an accelerated approval to…

Dr. Weisman Quoted in Philadelphia Inquirer Article about Tofersen

May 15, 2023 No Comments

On March 22, Weisman and his fellow advisers voted unanimously that the drug was ‘reasonably…

Statement of inclusion

Abington Neurological Associates is proud to offer clinical trials investigating potential treatments in AD. Alzheimer’s is a terrible, fatal disease, which currently has no disease modifying treatment, and affects people of all creeds, nationalities and ethnicities. We welcome any individual with Alzheimer’s disease into these trials and will continue to do so. In previous trials, we are pleased to have contributed data from traditionally under-diagnosed and under-studied minority populations. ANA is committed to recruiting subjects until AD is cured.

Joining a trial is a highly personal decision. Aside from long lists of exclusion criteria, trials are not the right fit for everyone or for every family. Culture does play a role in this decision making. We aim to remove the barriers we can.